Talking about production costs of drugs, as an input to price, is as relevant as discussing download cost as input to software prices (or any digital media prices).
https://en.wikipedia.org/wiki/Remdesivir#Manufacturing_and_d...
It seems a little bit like producing Whisky: you can't just decide now to produce a huge batch of 12-year-old Lagavulin and have it ready next month.
I believe Gilead's target is 500,000 doses by November. In an ideal world, they'd probably want to sell doses to just about every person with COVID, but they can't, due to supply constraints.
I thought the big Indian manufacturers already just-about ignored patents, these only restrict what can be shipped to the west.